18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: Poor predictive value of international harmonization project interpretation

Journal of Nuclear Medicine

Volumn 52, Issue 3, 2011, Pages 386-392

  Cashen, Amanda F ^a,b   Dehdashti, Farrokh ^a,b   Luo, Jingqin ^a,b   Homb, Andrew ^b   Siegel, Barry A ^a,b   Bartlett, Nancy L ^a,b  

^a USA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18F FDG; Non Hodgkin lymphoma; PET; PET CT; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVENT FREE SURVIVAL; HUMAN; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; STANDARDIZATION; TREATMENT RESPONSE; ALGORITHM; B CELL LYMPHOMA; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; IMAGE ENHANCEMENT; MALE; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VINCRISTINE;

EID: 79952786300     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.082586     Document Type: Article

References (26)

1. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica. 2006;91:522-529.
2. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: a systematic review. J Nucl Med. 2008;49:13-21.
3. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586. (Pubitemid 350002966)
4. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-578. (Pubitemid 350002965)
5. 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1356-1363.
6. 18F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma. Hematology. 2007;12:423-430.
7. Jerusalem G, Beguin Y, Fassotte M, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non- Hodgkin's lymphoma. Haematologica. 2000;85:613-618. (Pubitemid 30450941)
8. Mikhaeel N, Hutchings M, Fields P, O'Doherty M, Timothy A. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514-1523. (Pubitemid 41222425)
9. 18F]fluoro-2-deoxy-D- glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376-1381.
10. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-b-cell lymphoma. N Engl J Med. 2002;346:235-242. (Pubitemid 34438862)
11. Fruchart C, Reman O, Le Stang N, et al. Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study. Leuk Lymphoma. 2006;47:2547-2557. (Pubitemid 44932645)
12. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
13. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006;107:2678-2687. (Pubitemid 44845624)
14. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large b-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-1914.
15. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma: comparison with CT. Leuk Lymphoma. 2000;39:543-553. (Pubitemid 32162393)
16. Radford J, O'Doherty M, Barrington S, et al. Results of the 2nd planned interim analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin lymphoma and a 'negative' FDG-PET scan after 3 cycles ABVD [abstract]. Blood. 2008;112:369.
17. Mikhaeel NG. Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now? Leuk Lymphoma. 2009;50:1931-1936.
18. 18F-FDG PET for prediction of prognosis in patients with diffuse large b-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626-1632.
19. Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009;20:309-318.
20. Pregno P, Chiappella A, Bello M, et al. Interim 18-FDG-positron emission tomography/computed tomography (PET) failed to predict different outcome in diffuse large b-cell lymphoma (DLBCL) patients treated with rituximab-CHOP [abstract]. Blood. 2009;114:99.
21. Safar V, Dupuis J, Jardin F, et al. Early 18fluorodeoxyglucose PET scan as a prognostic tool in diffuse large b-cell lymphoma patients treated with an anthracycline-based chemotherapy plus rituximab [abstract]. Blood. 2009;114:98.
22. Micallef IN, Maurer MJ, Witzig TE, et al. PET scan results of NCCTG N0489: epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large b-cell lymphoma [abstract]. Blood. 2009;114:137.
23. Kasamon YL, Wahl RL, Ziessman HA, et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on mid-treatment FDG-PET scanning. Biol Blood Marrow Transplant. 2009;15:242-248.
24. Moscowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large b-cell lymphoma. J Clin Oncol. 2010;28:1893-1903.
25. Horning SJ, Juweid ME, Schoder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775-777.
26. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257-1260.